Based in Saint Contest near Caen, the company founded by Bruno Laÿ relies on a team of top-level R&D engineers specialising in image processing and Artificial Intelligence.
ADCIS’ expertise in the field of computer vision is recognised both in France and internationally. The company, which develops the Aphelion image processing software, counts major names such as Bayer, L’Oréal and Novartis among its customers.
Well-connected to the French INSERM research laboratory networks, ADCIS deploys its expertise in the healthcare sector (ophthalmology, dermatology, life sciences) as well as in a number of cutting-edge industrial fields (drones, materials, authentication, etc.).
The ADCIS team now comprises 10 employees, including 8 engineers specialising in image processing, led by François Potevin, Director of Computer Vision and Director of Critical Care Product Marketing.
In particular, ADCIS is in charge of OphtAI’s AI algorithms, which process retinal images to detect pathologies. A new project is also underway to detect neurological pathologies.
Another AI developed by the team is corneal image processing. This project should result in an online platform called MyCornea, enabling ophthalmologists to check whether the cornea has been grafted.
Finally, the last ophthalmology project is aimed at blepharoplasty (eyelid surgery) to compare the differences before and after surgery.
OphtAI uses an AI developed by ADCIS that detects ocular pathologies by analysing photos of the retina: RDR, diabetic macular oedema, glaucoma, AMD and Drusen.
This artificial intelligence has been trained on several hundred thousand photos annotated by the retinologist experts in the OphDiaT network.
ADCIS is also turning its attention to mammography, developing AI to reduce the pain of the examination by controlling the force exerted by the machine on the patient’s chest. In this way, AI will ensure that mammograms are taken correctly.
